Form D · Biotechnology
Biothea Pharma, Inc.
Boston, MA · CIK 0001877163
Offering snapshot reported Aug 6, 2021 · SEC filing
- Reported sold
- $22M Offering amount: $22M
- Investors reported
- 30 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 23, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2021 | Initial | $22,000,000 | No comparison | 30 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-409135
Source: Form D, filed Aug 6, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anthony Aiudi | Director |
| Torbjorn Bjerke | Director |
| Marina S. Bozilenko | Director, Executive |
| Andrea J. Corcoran | Executive |
| Rohit Mehta | Executive |
| Jean Pierre Sommadossi, Ph.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
125 Summer Street
Boston, MA, 02110
Boston, MA, 02110